Curtin University Homepage
  • Library
  • Help
    • Admin

    espace - Curtin’s institutional repository

    JavaScript is disabled for your browser. Some features of this site may not work without it.
    View Item 
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item

    Heart failure following oncological treatment

    Access Status
    Fulltext not available
    Authors
    Marangou, J.
    Redfern, A.
    Haddad, T.
    Rankin, J.
    Dwivedi, Girish
    Date
    2018
    Type
    Journal Article
    
    Metadata
    Show full item record
    Citation
    Marangou, J. and Redfern, A. and Haddad, T. and Rankin, J. and Dwivedi, G. 2018. Heart failure following oncological treatment. Current Opinion in Cardiology. 33 (2): pp. 237-244.
    Source Title
    Current Opinion in Cardiology
    DOI
    10.1097/HCO.0000000000000488
    ISSN
    0268-4705
    School
    School of Pharmacy and Biomedical Sciences
    URI
    http://hdl.handle.net/20.500.11937/73139
    Collection
    • Curtin Research Publications
    Abstract

    © 2018 Wolters Kluwer Health, Inc. All rights reserved. Purpose of review The aim of this review is to give the reader an up-to-date overview of the progress made in the burgeoning field of cardio-oncology, encompassing oncological treatments conferring risk, prediction strategies to identify patients at risk, imaging and biomarker monitoring for emergent or subclinical toxicity and prevention in primary and secondary settings with a focus on heart failure. Recent findings The rapid recent advances in cancer management, particularly with the expansion of targeted and immunotherapies, have led to substantial improvements in outcome, but have also added to the potential causes of cardiac toxicity, which can lead to heart failure. Against this, there has been progression in the field of imaging for cardiac toxicity, identification of at-risk individuals and the clarification of the role of therapy for prevention and treatment of cardiac toxicity. Summary The findings described in this review provide guidance to clinicians in order to direct monitoring strategy and therapy choice, both in the individual with preexisting cardiac comorbidities and in those predicted to be at the highest risk of cardiac toxicity wherever therapy elements carrying cardiac risk are considered oncologically appropriate.

    Related items

    Showing items related by title, author, creator and subject.

    • Adjuvant trastuzumab in HER2-positive breast cancer.
      Slamon, D.; Eiermann, W.; Robert, N.; Pienkowski, T.; Martin, M.; Press, M.; Mackey, J.; Glaspy, J.; Chan, Arlene; Pawlicki, M.; Pinter, T.; Valero, V.; Liu, M.; Sauter, G.; von Minckwitz, G.; Visco, F.; Bee, V.; Buyse, M.; Bendahmane, B.; Tabah-Fisch, I.; Lindsay, M.; Riva, A.; Crown, J.; Breast, C. (2011)
      Trastuzumab improves survival in the adjuvant treatment of HER-positive breast cancer, although combined therapy with anthracycline-based regimens has been associated with cardiac toxicity. We wanted to evaluate the ...
    • A preoperative risk prediction model for 30-day mortality following cardiac surgery in an Australian cohort
      Billah, B.; Reid, Christopher; Shardey, G.; Smith, J. (2010)
      Background: Population-specific risk models are required to build consumer and provider confidence in clinical service delivery, particularly when the risks may be life-threatening. Cardiac surgery carries such risks. ...
    • Pharmacists' active interventions in a children's hospital: an Australian context.
      Ramadaniati, H.; Lee, Ya Ping; Hughes, J. (2014)
      PURPOSE: This study documented pharmacists’ active interventions leading to changes in drug therapy in order to (i) compare the nature of clinical pharmacists’ active interventions made in different practice settings ...
    Advanced search

    Browse

    Communities & CollectionsIssue DateAuthorTitleSubjectDocument TypeThis CollectionIssue DateAuthorTitleSubjectDocument Type

    My Account

    Admin

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Follow Curtin

    • 
    • 
    • 
    • 
    • 

    CRICOS Provider Code: 00301JABN: 99 143 842 569TEQSA: PRV12158

    Copyright | Disclaimer | Privacy statement | Accessibility

    Curtin would like to pay respect to the Aboriginal and Torres Strait Islander members of our community by acknowledging the traditional owners of the land on which the Perth campus is located, the Whadjuk people of the Nyungar Nation; and on our Kalgoorlie campus, the Wongutha people of the North-Eastern Goldfields.